EpiVacCorona
 | |
| Data klinikal | |
|---|---|
| Kaedah pemberian | Intraotot |
| Status perundangan | |
| Status perundangan |
|
| Pengecam | |
| DrugBank | |
EpiVacCorona (Bahasa Rusia: ЭпиВакКорона, tr. EpiVakKorona) ialah vaksin COVID-19 yang dibangunkan oleh Institut Vector.[1][2][3] Vaksin EpiVacCorona mengandungi fragmen-fragmen yang diekstrak dari antigen peptida sintesis virus. Vaksin berasaskan antigen tersebut menghasilkan reaksi imun melawan COVID-19 dan menggalakkan pengembangan imuniti lebih lanjut.[4]
Perlaksanaan
[sunting | sunting sumber]Pada 14 Oktober 2020, Presiden Vladimir Putin mengumumkan bahawa vaksin tersebut telah diluluskan.[5]
Rujukan
[sunting | sunting sumber]- ^ "Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 (EpiVacCorona)". ClinicalTrials.gov. United States National Library of Medicine. 22 September 2020. NCT04368988. Dicapai pada 16 November 2020.
- ^ "Russian EpiVacCorona Vaccine Has No Adverse Effects". OREANDA-NEWS (dalam bahasa Inggeris). 13 January 2021.
- ^ "Over 1,400 volunteers get Russia's first EpiVacCorona vaccine jab". TASS (dalam bahasa Inggeris). 15 December 2020.
- ^ "State Research Center of Virology and Biotechnology: COVID-19 Vaccine Patented". Federal Service for Intellectual Property. 30 September 2020. Dicapai pada 17 January 2021.
- ^ "Совещание с членами Правительства". President of Russia. 14 October 2020.
Kategori:
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Dadah yang tidak mempunyai kod ATC
- Articles containing unverified chemical infoboxes
- Infobox drug tracked parameters
- Vaksin COVID-19